MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 146022 | Name: CAN-508

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CAN-508 is a small molecule compound primarily studied for its potential use in cancer therapy. It acts as an inhibitor of specific signaling pathways involved in tumor cell growth and survival, particularly targeting the MAPK/ERK pathway. By inhibiting this pathway, CAN-508 can disrupt cancer cell proliferation and induce apoptosis, making it a promising candidate for the treatment of various cancers. Its mechanism of action involves the selective inhibition of key enzymes that regulate cell cycle progression and cell survival, ultimately leading to reduced tumor growth.

Chemical Structure

CAN-508
CAN-508
CAS#140651-18-9

Theoretical Analysis

MedKoo Cat#: 146022

Name: CAN-508

CAS#: 140651-18-9

Chemical Formula: C9H10N6O

Exact Mass: 218.0900

Molecular Weight: 218.22

Elemental Analysis: C, 49.54; H, 4.62; N, 38.51; O, 7.33

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CAN-508; CAN508; CAN 508;
IUPAC/Chemical Name
(E)-4-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
InChi Key
AYZRKFOEZQBUEA-OUKQBFOZSA-N
InChi Code
1S/C9H10N6O/c10-8-7(9(11)15-14-8)13-12-5-1-3-6(16)4-2-5/h1-4,16H,(H5,10,11,14,15)/b13-12+
SMILES Code
NC1=C(\N=N\C2=CC=C(O)C=C2)C(N)=NN1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 218.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25;8(17):28696-28710. doi: 10.18632/oncotarget.15645. PMID: 28404924; PMCID: PMC5438684. 2: Pisár M, Schütznerová E, Hančík F, Popa I, Trávníček Z, Cankař P. Modification of Boc-Protected CAN508 via Acylation and Suzuki-Miyaura Coupling. Molecules. 2018 Jan 12;23(1):149. doi: 10.3390/molecules23010149. PMID: 29329219; PMCID: PMC6017724. 3: Baumli S, Hole AJ, Noble ME, Endicott JA. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508. ACS Chem Biol. 2012 May 18;7(5):811-6. doi: 10.1021/cb2004516. Epub 2012 Feb 10. PMID: 22292676; PMCID: PMC3355656. 4: Kryštof V, Rárová L, Liebl J, Zahler S, Jorda R, Voller J, Cankař P. The selective P-TEFb inhibitor CAN508 targets angiogenesis. Eur J Med Chem. 2011 Sep;46(9):4289-94. doi: 10.1016/j.ejmech.2011.06.035. Epub 2011 Jul 3. PMID: 21777997. 5: Jing L, Tang Y, Xiao Z. Discovery of novel CDK inhibitors via scaffold hopping from CAN508. Bioorg Med Chem Lett. 2018 May 1;28(8):1386-1391. doi: 10.1016/j.bmcl.2018.02.054. Epub 2018 Mar 8. PMID: 29550093. 6: Said MA, Eldehna WM, Nocentini A, Fahim SH, Bonardi A, Elgazar AA, Kryštof V, Soliman DH, Abdel-Aziz HA, Gratteri P, Abou-Seri SM, Supuran CT. Sulfonamide- based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation. Eur J Med Chem. 2020 Mar 1;189:112019. doi: 10.1016/j.ejmech.2019.112019. Epub 2020 Jan 2. PMID: 31972394.